TABLE 2.
Hematological malignancies | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Target | CD19 | BCMA | CD22 | CD20 | CD123 | CD33 | CD30 | CD38 | CS1 | TAA b |
Approx. number of active therapies | 542 | 166 | 80 | 64 | 60 | 39 | 38 | 30 | 22 | 2 |
Solid tumors | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Target | HER2 | MSLN | EGFR | GD2 | GPC2/3 | MUC1 | PSMA | NY‐ESO‐1 | EBV | TAA b |
Approx. number of active therapies | 59 | 53 | 50 | 49 | 39 | 34 | 28 | 5 | 4 | 5 |
Table was derived from figure 2 in Upadhaya et al. 10 If the actual number is not available in the figure, digitization is used to estimate the number.
Undisclosed tumor‐associate antigen.